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Aim AZD1305 is a combined ion channel blocker developed for the treatment of atrial fibrillation (AF). The aim of this
study was to determine whether AZD1305 was effective in converting AF to sinus rhythm (SR).
Methods
and results
Patients with AF episodes of duration 3 h to 3 months were randomized in a 3:1 ratio to receive a maximum 30 min
intravenous infusion of AZD1305 or matching placebo. The primary efficacy endpoint was the proportion of patients
converting within 90 min of the start of infusion, after which patients who had not converted were to undergo direct
current (DC) cardioversion. Four ascending AZD1305 dose groups were assigned sequentially, with dose rates of 50,
100, 130, and 180 mg/h.
A total of 171 patients were randomized. Pharmacological conversion was achieved in 0 of 43 patients (0%) in the
placebo group, and in 2 of 26 (8%; P ¼ 0.14 vs. placebo), 8 of 45 (18%; P ¼ 0.006), 17 of 45 (38%; P, 0.001), and 6 of
12 patients (50%; P, 0.001) in AZD1305 dose groups 1–4, respectively. Maximum QTcF (QT interval corrected
according to Fridericia’s formula) generally increased dose-dependently up to a plateau, although there was wide vari-
ation between patients. Two patients experienced torsade de pointes (TdP): one patient without symptoms in dose
group 3, and one patient requiring DC defibrillation in dose group 4. Both patients recovered without sequelae.
Conclusions AZD1305 was effective in converting AF to SR, but was associated with QT prolongation and TdP. The benefit–risk
profile was judged as unfavourable and the AZD1305 development programme was discontinued.
Clinical trial registration: http://clinicaltrials.gov identifier NCT00915356.
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Introduction
Atrial fibrillation (AF) is the most common tachyarrhythmia encoun-
tered in clinical practice and accounts for a significant part of the
health service expenditure in developed countries.1 Currently
available drugs for rhythm control are not highly effective, and are
sometimes associated with adverse reactions or pro-arrhythmia,
especially in patients with predispositions such as concomitant struc-
tural heart disease.2 Consequently, there is a need for well-tolerated
drugs that can effectively establish and maintain sinus rhythm (SR).3
* Corresponding author. Tel: +46 31 776 1000; fax: +46 31 776 3737, Email: anders.r.berggren@astrazeneca.com
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2011. For permissions please email: journals.permissions@oup.com.
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AZD1305 is a novel combined ion channel blocker that
delays myocardial repolarization and increases refractoriness.4
AZD1305 is rapidly and extensively distributed and has a moderate
bioavailability due to first-pass metabolism, primarily via cyto-
chrome P450 3A4. The terminal half-life of AZD1305 is 5–12 h
in healthy subjects (AstraZeneca on file). With effects on potass-
ium, calcium, and sodium currents, AZD1305 has similar channel-
blocking properties to its predecessor compound AZD7009.5 –7
Although AZD7009 was highly effective in the conversion of AF
of up to 3 months duration, it was found to induce flu-like symp-
toms in an elderly population on repeat oral administration, which
led to discontinuation of its development.8– 10 In contrast, while
AZD1305 has shown promising antiarrhythmic effects in preclinical
studies, it has not been associated with flu-like symptoms in clinical
trials.11–13 In an invasive electrophysiology study in patients with
atrial flutter (AFl), AZD1305 increased the effective refractory
periods in both the right and left atria, and in the right ventricle.13
The aims of the present study were to show that AZD1305 was
effective in the conversion of AF to SR, and to evaluate the dose2
response relationship for conversion and QT effects. Instead of a
traditional parallel group design, a dose escalation design was
chosen to allow for corrections underway if the initial assumptions
proved to be wrong.
Methods
Patients
Eligible patients were men and post-menopausal women between 20
and 80 years of age with ongoing symptomatic AF of ≥3 h and
≤3 months duration and with a clinical indication for direct current
(DC) cardioversion. Patients had to be on effective anticoagulation
therapy according to national or international guidelines. Cardioversion
could be done in patients with short-lasting AF without anticoagulation
provided that transoesophageal echocardiography was normal. Impor-
tant exclusion criteria were: estimated glomerular filtration rate
,30 mL/min; elevated hepatic enzymes (alanine transaminase .3
times upper limit of normal); blood haemoglobin ,100 g/L
(6.2 mmol/L), potassium in serum or plasma ,3.8 mmol/L at randomiz-
ation; cardioversion of AF or AFl within 2 weeks of randomization, or
unsuccessful cardioversion of current AF episode; systolic blood
pressure ,100 or .180 mmHg; heart failure New York Heart Associ-
ation class III or IV; left ventricular ejection fraction ,40%; bradycardia
[,50 beats per minute (bpm)]; personal or family history of torsade de
pointes (TdP), any other polymorphic ventricular tachycardia, long QT
syndrome or Brugada syndrome, or personal history of sustained
(.30 s) monomorphic ventricular tachycardia; QTcF (QT interval cor-
rected according to Fridericia’s formula) .440 ms (during AF the mean
of ≥5 consecutive RR intervals with consecutive QT intervals); com-
plete bundle branch block, or any QRS duration ≥120 ms; use of any
antiarrhythmic drug class I or III, QT prolonging drug and/or drugs
that are strong or moderate inhibitors of CYP3A4 (with the exception
of verapamil), including St John’s Wort, within five half-lives before
randomization (3 months for amiodarone).
Study design
This double-blind, randomized, placebo-controlled, dose-escalation
study (clinicaltrials.gov identifier NCT00915356) was carried out at 33
sites in Czech Republic, Hungary, Slovakia, Poland, The Netherlands,
Sweden, Norway, and Denmark. The study was approved by
appropriate Independent Ethics Committees and was carried out in
accordance with the Declaration of Helsinki and Good Clinical Practice.
Written informed consent was obtained from all patients. Patients were
randomized in a 3:1 ratio to receive AZD1305 or matching placebo as an
intravenous infusion, with a maximum infusion time of 30 min. Infusion
was to be stopped before 30 min if successful conversion to SR was
achieved or if significant adverse effects occurred, including conversion
to any rhythm other than SR or AFl; a QTcF .550 ms, manually defined
and calculated from 12-lead echocardiogram (ECG) printouts,
measured twice ≥3 min apart (during AF, QTcF was to be calculated
during a heart rate of 50 to 100 bpm as the mean of ≥5 consecutive
beats); heart rate ,40 bpm for .30 s; systolic blood pressure (SBP)
,90 mmHg for .1 min resulting in medical intervention. Conversion
to SR was deemed to have occurred if SR was maintained for ≥1 min.
If a patient had not converted to SR within 90 min of the start of infusion,
DC cardioversion was to be carried out according to local protocol
between 91 and 180 min. In case of AF recurrence, DC cardioversion
was allowed during the study period. Patients were to remain in the hos-
pital for at least 24 h after start of infusion and until the QTcF was
≤500 ms. A 12-lead Holter recording was started within 30 min
before the start of infusion and continued until discharge. In addition,
12-lead ECGs were recorded for safety evaluation by the investigator,
and patients were telemetrically monitored. Patients returned to the
clinic for a follow-up examination, including 12-lead ECG, between 13
and 18 days after infusion.
Patients were allocated by an external vendor (call centre), which
the investigator contacted to obtain each patient’s randomization
code. In order to ensure blinding of clinicians and patients, solutions
of AZD1305 and placebo were identical in appearance and were pack-
aged and labelled identically, with label codes held in sealed envelopes
in case of emergency.
There were four planned sequential dose groups, and a fifth dose
group was optional if the balance between efficacy variables and safety
was not sufficiently established in the first four groups. The infusion
rate was 120 mL/h in all dose groups, and the AZD1305 dose rates
were 50, 100, 130, and 180 mg/h in dose groups 1, 2, 3, and 4, respect-
ively, with target plasma concentration after 30 min infusion of 0.5, 1.1,
1.7, and 2.0 mmol/L. The first dose level was chosen to provide the
lowest AZD1305 plasma concentration expected to have an effect on
conversion of AF to SR based on effects on the atrial effective refractory
period in a study of AZD1305 in patients with AFl.13 The first dose level
would also give guidance on how well pharmacokinetic (PK) estimations
from previous studies in healthy volunteers and patients with AFl were
reflected in patients with AF. In order to meet these objectives, the first
dose group required only about half the number of patients of sub-
sequent dose groups. A blinded Adjudication Committee consisting of
three external experts and one AstraZeneca cardiologist independent
of the project reviewed all 12-lead Holter reports and analysed and
classified significant arrhythmias (other than AF or AFl), pauses ≥3 s,
and wide QRS complex (WQRS) tachycardias (QRS ≥120 ms and
≥120 bpm) of ≥3 beats.
Statistics
The primary efficacy measure was the proportion of patients converted
from AF to SR within 90 min from start of infusion. Pairwise compari-
sons between AZD1305 dose groups and placebo were performed
using Fisher’s exact test. A logistic regression model was used to
address the hypothesis of a significant dose2response relationship,
with dose rate as a continuous covariate. Secondary efficacy measures
included time to conversion and the proportion of patients with an
early relapse of AF, defined as .30 s of AF or AFl occurring within
5 min from conversion to SR. The primary safety variable was QTcF.
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The dose2response relationship for QTcF was estimated using an Emax
model, with dose rate as an explanatory variable.
The sample size calculation was based on the conversion rate in
dose group 2, which was assumed to be 20%, as compared with 1%
for placebo. Randomizing 30 patients to the first dose group and
60 patients to each subsequent dose group was assumed to provide
for ≥40 evaluable patients on AZD1305 in each of dose groups 2,
3, and 4, and an aggregate of ≥50 evaluable patients on placebo.
Using Fisher’s exact test, two-sided, at a significance level of 5%, this
number of patients would provide a power of 82% to test the hypoth-
esis of no difference between AZD1305 in dose group 2 vs. combined
placebo.
Results
The first patient was enrolled on 25 May 2009, and the last patient
on 4 December 2009. A total of 228 patients were enrolled, 171
patients were randomized, and 170 completed the study (Figure 1).
All 171 patients received an infusion, and were included in the
intent-to-treat efficacy analyses and safety analyses. Six patients
were excluded from the per-protocol (PP) analyses prior to
unblinding due to major protocol deviations (Figure 1). Patients
were well matched between groups at baseline, except for conges-
tive heart failure, which was more common in AZD1305 dose
group 2 than in the other groups (Table 1). All patients were
Caucasian. The trial was stopped during recruitment into dose
group 4 when a patient experienced a sustained TdP requiring defi-
brillation, which constituted a pre-defined study stopping criterion.
As a result, dose group 4 contains fewer patients than planned.
Efficacy
The proportion of patients treated with AZD1305 who converted
to SR within 90 min of the start of infusion was 8, 18, 38, and 50%
in dose groups 1, 2, 3, and 4, respectively (Figure 2). None of the
patients in the placebo group converted to SR before DC cardio-
version. The difference between AZD1305 and placebo was
statistically significant for dose groups 2, 3, and 4 (Figure 2). More-
over, there was a statistically significant dose2response relation-
ship (P, 0.001) between AZD1305 dose and conversion within
90 min. The pharmacological conversion rate was inversely pro-
portional to the duration of the AF episode (Table 2). Most
Screened n = 228
Randomized n = 171
Treated n = 171
Completed assessments n = 170
1patient withdrew consent
(dose group 1, AZD1305)
ITT/safety set n = 171
6 patients excluded from
per-protocol analysis*
Infusion rate 200 mL/h, n = 3
Atrial flutter at randomization, n = 2
Amiodarone within 3 months
before enrollment, n = 1Per-protocol set n = 165
*All 6 major protocol deviations that warranted exclusion from per-protocol analysis were
identified prior to unblinding.
Dose group
1
2
3
4
26
45
45
12
9
15
14
5
AZD1305, n Placebo, n
Figure 1 Patient disposition and analysis sets.
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conversions with AZD1305 occurred between 10 min and 1 h
after the start of infusion (Figure 2). In addition, one patient in
dose group 2 and two patients in dose group 4 converted with
AZD1305 .90 min after start of infusion. The proportion of
patients with relapse of AF within 5 min was low: 1 out of 33
patients converted on AZD1305 and 4 out of 108 DC cardio-
verted patients. Of the 141 patients converted either by
AZD1305 or by DC cardioversion, 136 (96%) were still in SR at
24 h, and 91 (65%) were still in SR at the follow-up visit on day
13–18 (Table 2). In AZD1305 dose group 3, 11 of 33 patients
(33%) with a maximal QTcF ≤500 ms converted from AF to SR,
compared with 6 of 12 patients (50%) with a maximal QTcF
.500 ms. This relationship between maximal QTcF and conver-
sion rate was not seen in the other AZD1305 dose groups,
which exhibited similar conversion rates between patients with
maximal QTcF ≤500 and .500 ms.
Pharmacokinetics
The PK of AZD1305 was predictable based on the mean maximal
plasma concentrations being proportional to the dose given.
However, there was large variability in measured AZD1305
plasma concentrations between patients within each dose group.
Some of this variability may be due to variations in infusion time
between patients, leading to various AZD1305 doses within a
dose group. In some patients, the time of Cmax did not coincide
with the time of stop of the infusion, e.g. in one patient where
the only available plasma sample was taken 20 h after stop of
infusion, not reflecting the actual Cmax of AZD1305.
Effects on QT and QRS intervals
QTcF increased with increasing AZD1305 plasma concentration
and appeared to reach a plateau at high plasma concentrations
(Figure 3). Twenty-eight patients (22%) receiving AZD1305
reached maximum QTcF values .500 ms, including five with
values between 550 and 600 ms, and three with values
.600 ms. Typically, individual maximal QTcF occurred later in
time than AZD1305 Cmax, with a delay of several hours in many
patients. There were wide variations in QTcF response between
patients having similar exposure to AZD1305 (Figure 3A). None
of the seven patients with the highest observed AZD1305
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Table 1 Demographics and baseline characteristics
AZD1305 treatment group
Mean+ SD unless otherwise stated 1 (n5 26) 2 (n 5 45) 3 (n 5 45) 4 (n5 12) Placebo (n5 43)
Age, years 65+9 65+7 64+10 66+7 66+9
Female/male, n 9/17 17/28 14/31 4/8 18/25
Weight, kg 93+16 92+13 88+17 93+21 86+13
BMI, kg/m2 31+6 32+6 29+4 31+5 30+4
SBP, mmHg 131+14 134+15 132+15 138+17 132+19
DBP, mmHg 81+10 82+12 83+10 88+13 84+11
Heart rate, bpm 87+20 91+19 87+21 82+14 93+23
QTcF interval, ms 400+22 400+28 398+25 410+32 399+25
QRS interval, ms 89+7 91+11 94+12 96+11 88+7
Left atrium area, cm2, n 24+6 (18) 22+5 (35) 24+6 (37) 25+4 (10) 24+6 (38)
AF duration, days 44+26 41+25 39+27 47+31 44+26
AF duration category, n (%)
0–7 days 3 (12) 5 (11) 7 (16) 1 (8) 5 (12)
8–30 days 5 (19) 13 (29) 16 (36) 4 (33) 8 (19)
31–92 days 18 (69) 27 (60) 22 (49) 7 (58) 30 (70)
Selected concomitant medications, n (%)
Beta blocker 20 (77) 39 (87) 41 (91) 12 (100) 38 (88)
ACE inhibitor 14 (54) 27 (60) 20 (44) 4 (33) 15 (35)
ARB 3 (12) 4 (9) 6 (13) 3 (25) 3 (7)
Lipid reducing agent 8 (31) 16 (36) 23 (51) 5 (42) 13 (30)
Calcium antagonist 9 (35) 11 (24) 16 (36) 1 (8) 18 (42)
Digoxin 5 (19) 8 (18) 6 (13) 3 (25) 5 (12
Diuretics 12 (46) 30 (67) 20 (44) 7 (58) 24 (56)
Comorbid conditions affecting ≥20% of patients in any group, n (%)
Hypertension 22 (85) 40 (89) 35 (78) 11 (92) 30 (70)
Diabetes mellitus 6 (23) 13 (29) 6 (13) 2 (17) 3 (7)
Congestive heart failure 1 (4) 10 (22) 4 (9) 1 (8) 5 (12)
BMI, body mass index; ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; DBP, diastolic blood pressure.
Pharmacological cardioversion of atrial fibrillation 1151
by guest on January 16, 2017
D
ow
nloaded from
 
Figure 2 Pharmacological and direct current conversion (intent-to-treat set). (A) Conversion rate; (B) time to conversion.
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Table 2 Conversion from atrial fibrillation to sinus rhythm
AZD1305 dose group
Number of patients (%) 1 (n5 26) 2 (n 5 45) 3 (n5 45) 4 (n5 12) Placebo (n5 43)
Pharmacological conversion by AF episode duration
,7 days 0/3 (0) 2/5 (40) 5/7 (71) 1/1 (100) 0/5 (0)
8–30 days 0/5 (0) 4/13 (31) 6/16 (38) 2/4 (50) 0/8 (0)
31 days–3 months 2/18 (11) 2/27 (7) 6/22 (27) 3/7 (43) 0/30 (0)
Total pharmacological conversion within 90 min 2/26 (8) 8/45 (18) 17/45 (38) 6/12 (50) 0/43 (0)
Total pharmacological and DC conversion 24/26 (92) 34/45 (76) 40/45 (89) 9/12 (75) 34/43 (79)
Patients in SR
90 mina 2 (8) 8 (18) 17 (38) 6 (50) 0 (0)
24 hb 23 (88) 34 (76) 36 (80) 10 (83) 33 (77)
Day 13–18b 14 (56)c 23 (51) 25 (56) 7 (58) 22 (51)
aAfter pharmacological conversion.
bAfter pharmacological conversion or DC cardioversion.
cn ¼ 25 because one patient withdrew consent for assessment.
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plasma concentrations, i.e. above 2.2 mmol/L, had an individual
maximal QTcF .520 ms. There was no effect on the QRS interval
in any of the dose groups.
Safety
There were no deaths during the study and no discontinuations of
infusion due to adverse events (AEs). On the treatment day, nine
patients (7%) treated with AZD1305 experienced 11 AEs compared
with one patient (2%) with 2 AEs in the placebo group (Table 3).
From day 2 until the follow-up visit, 37 patients treated with
AZD1305 (29%) reported AEs compared with 11 patients in the
placebo group (26%). Most AEs were of cardiovascular origin, as
expected for a patient population with AF undergoing cardioversion.
Ten patients experienced 13 serious AEs (SAEs) during the overall
study period. Three of these SAEs were considered by the investi-
gator to be related to study treatment: cardiac asthma, TdP, and ven-
tricular tachycardia. The other SAEs were AF (n ¼ 2), sinus
bradycardia, cerebrovascular accident, multiple drug overdose, tran-
sient ischaemic attack, urinary tract infection, pre-syncope, chronic
obstructive pulmonary disease, and abdominal wall haematoma.
A TdP occurred in a 72-year-old female patient who received
AZD1305 in dose group 3 (actual dose 65 mg). The patient had
Figure 3 Individual patient maximum QTcF (per-protocol analysis). (A) Maximum QTcF vs. Cmax; (B) maximum QTcF vs. dose rate, with Emax
model. *maximal value in one patient due to post hoc measurement initiated by torsade de pointes event. QTcF, QT interval corrected accord-
ing to Fridericia’s formula.
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a medical history including congestive heart failure, and her medi-
cation included acenocoumarol, amlodipine, valsartan, metoprolol,
spironolactone, furosemide, potassium, and atrovastatin. She was
treated for heart failure with spironolactone, potassium, and gly-
ceryl trinitrate (iv) four days prior to the AZD1305 infusion, had
QTcF in the upper reference range (443 ms), and had S-K+ of
3.6 mmol/L. Five and a half hours after the infusion, the patient
had a TdP of 16 beats without any symptoms during excessive pro-
longation of the QTcF interval. The patient continued to have runs
of TdP during the next few hours, the longest consisting of 70
beats (19 s) without any symptoms. The patient received potass-
ium and magnesium substitution and recovered without sequelae.
The patient’s observed Cmax was 2.0 mmol/L. The patient also
received furosemide 1 h after the infusion, and altogether there
were signs of an uncompensated heart failure, indicating that
randomizing this patient was a protocol violation. The event was
judged by the investigator to be related to investigational
product and furosemide.
A ventricular tachyarrhythmia occurred in a 72-year-old female
patient who received AZD1305 in dose group 4 (planned dose
90 mg). The patient had a medical history of hypertension and
her medication included warfarin, furosemide, potassium, meto-
prolol, digoxin, perindopril, atorvastatin, and trimetazidine.
Twenty minutes after having received the full infusion, early pre-
mature ventricular beats were observed. Shortly afterwards, she
had a polymorphic ventricular tachycardia with haemodynamic
consequences and was DC cardioverted to SR. The QTcF interval
was extensively prolonged. After DC cardioversion she had sinus
bradycardia. She received intravenous isoprenaline, potassium,
and magnesium, and recovered without sequelae. The observed
Cmax was 3.25 mmol/L. The ventricular tachyarrhythmia was sub-
sequently adjudicated to be TdP. At control, it was detected that
the patient had been given a higher dose than intended. Thus,
135–150 mg of AZD1305 was infused during 30 min instead of
the planned 90 mg.
There was one RR interval .3 s (8.2 s), which occurred in a
patient in the placebo group, and one ventricular pause .5 s,
which occurred in a patient in AZD1305 dose group 2 (Table 3).
Most wide QRS tachycardias were observed during AF before con-
version, and were commonly caused by aberrant conduction.
There was a greater prevalence of wide QRS tachycardias in
AZD1305 dose groups 2 and 3 than the other groups, which
was partly due to arrhythmias of ventricular origin (Table 3).
Decisions by independent adjudicators were unanimous regarding
polymorphic ventricular tachycardia classified as TdP and TdP-like.
Discussion
AZD1305 was effective in converting AF to SR, with a conversion
rate of 50% within 90 min in the highest dose group, despite AF
episode durations up to 3 months. The pharmacological conver-
sion rate in the highest dose group was 67% including two
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Table 3 All-cause adverse events during the treatment day and adjudicated arrhythmias
AZD1305 dose group
Number of patients (%) 1 (n 5 26) 2 (n 5 45) 3 (n5 45) 4 (n 5 12) Placebo (n5 43)
Adverse events
Dyspnoea 1 (2) 2 (4)
Atrioventricular block first degree 1 (2)
Bradycardia 1 (8)
Dizziness 1 (8)
Feeling hot 1 (2)
Muscle spasms 1 (4)
Sinus bradycardia 1 (2)
Supraventricular tachycardia 1 (4)
Torsade de pointes 1 (2)
Ventricular tachycardia 1 (8)
Vomiting 1 (2)
Adjudicated arrhythmias
RR intervals 3–5 s 1 (2)
Ventricular pauses .5 s 1 (2)
Wide QRS complex tachycardias 4 (15) 15 (33) 16 (36) 2 (17) 7 (16)
SVT with aberration/bundle branch block 1 (4) 8 (18) 7 (16) 1 (8) 7 (16)
Monomorphic VT 3 (12) 7 (16) 8 (18) 1 (2)
Polymorphic VT 1 (4) 1 (2) 4 (9) 1 (8)
Torsade de pointes 1 (2) 1 (8)
Torsade de pointes like 1 (2)
SVT, supra-ventricular tachycardia.
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conversions occurring after 90 min. Consistent with established
experience of AF conversion,2 there appeared to be an inverse
relationship between conversion rate and AF episode duration.
Nevertheless, in this study the conversion rate was substantial
even in patients with AF episodes of .30 days duration, with
the caveat that the numbers involved were small. One possible
explanation could be that the balance between the potassium
and sodium channel blocking properties was advantageous, and
that the late sodium channel blockade permitted AZD1305 to
be given in doses that allowed QTcF values above 500 ms to be
reached with little risk of proarrhythmia. The rates of conversion
observed with AZD1305 were similar to those obtained with
the predecessor compound AZD7009.10
Generally, QTcF increased dose-dependently and appeared to
reach a plateau at higher doses. However, there was wide vari-
ation in maximum QTcF, and the highest observed QTcFs were
not associated with the highest AZD1305 plasma concentrations.
This finding suggests that although there is a relationship
between exposure to AZD1305 and QT prolongation, other
factors such as patient characteristics may be at least as impor-
tant in explaining why some patients exhibit more pronounced
QT prolongations than others. Interestingly, conversion rates
did not seem to differ with respect to maximal QTcF being
greater or less than 500 ms. The plateau phenomenon was
also seen with AZD7009, although at a lower QTcF level, and
the most likely explanation is that further QT prolongation at
higher doses was mitigated by late sodium channel inhibition.4
Sodium channel inhibition was observed in preclinical studies
with both AZD7009 and AZD1305,4,5,14 and this effect was
supported in clinical trials by increased QRS duration and/or
increases in other indices of conduction.9,13 This and/or other
actions of AZD1305 may have allowed us to explore higher
than usual QTcF levels without any untoward effects in most,
but unfortunately not all patients. Theoretically, if the resolution
of this potential mitigation of negative effects of the QT pro-
longation occurred faster than restitution of QT prolongation,
the patient could be left in an unguarded proarrhythmogenic
state for a period of time. In fact, in the present study there
was an absence of signs of sodium channel blockade while
QTcF restitution appeared to be delayed, with the maximal
QTcF values often occurring later than the time of Cmax. One
possible mechanism for this delay might be differences
between plasma and intracellular AZD1305 concentration and
clearance. Combining information from studies with AZD7009
and AZD1305, a striking phenomenon was that the few TdPs
that occurred following doses according to protocol were
detected not on the day of the study, but later, when the
Holter recordings were analysed. Development of the TdP
occurred hours after the end of the infusion and during a
remaining excessive QT prolongation, which slowly returned
to normal. The QTcF was followed according to protocol, and
the patients were kept in hospital until the QTcF had declined
to below 500 ms.
The occurrence of proarrhythmia raises questions and concerns.
In this study there were important protocol violations in relation
to both patients who developed TdP. Whether these circum-
stances are enough to explain the proarrhythmia, or whether
other, undetected, predispositions contributed will remain
unknown. However, 95% of the patients treated with AZD1305
did well, behaved as predicted regarding their QTcF response,
and had a QTcF ≤500 ms when measured 6 h after start of infu-
sion. The study results clearly tell us that when protocol violation
occurs, patients may experience unwanted reactions. However, it
also suggests that outlier reactions may occur in patients who
have in all respects been treated as intended. If AZD1305 had
ever reached the market, it is likely that similar events would
have occurred however carefully the safety procedures had been
followed. The results of the present study together with previous
results indicate that AZD1305 is a potentially torsadogenic drug
for which it would be difficult to guarantee a sufficient safety
margin in clinical practice. As a result, the development
programme of AZD1305 has been discontinued.
The efficacy of AZD1305 in converting patients from AF to
SR was greater and different from the action of currently avail-
able antiarrhythmic agents. The majority of patients in this
study (61%) had AF episode durations of 1–3 months, and the
conversion rates in these patients of 27 and 43%, respectively,
in AZD1305 dose groups 3 and 4 were greater than the conver-
sion rates of 19–22% reported for dofetilide and flecainide in
patients with similarly sustained AF durations.15 – 17 The pro-
portion of patients in the present study with AF durations of
,7 days was small (12%), and inferences must necessarily be
made with caution, nevertheless the rate of conversion in
AZD1305 dose group 3 (71%), compares favourably with
reported conversion rates for flecainide and dofetilide in
recent onset AF.18,19 Thus, it appears that AZD1305 achieved
a high success rate in a broad patient population, although the
effects on ventricular repolarization turned out to be unaccepta-
ble. It remains to be seen whether atrial-specific compounds in
development will reach the efficacy rates seen here, or
whether combined ion channel blockade can meet its theoretical
potential for effective conversion of AF with a favourable
side-effect profile.20,21
Limitations
This was a dose guiding study and the size and design of the study
was planned accordingly. The number of patients in each dose
group was decided based on the predicted success rate in intrave-
nous conversion. Nevertheless, proarrhythmia occurs infrequently
and unpredictably and in this respect the findings of the present
study should be allowed to be interpreted together with the pre-
vious experience in man.
Conclusions
Intravenous AZD1305 was effective in converting AF to SR, with a
significant dose2response relationship. Although there was wide
variation in QTcF response, QTcF interval generally increased
with increasing dose and appeared to reach a plateau at high
doses. Two patients experienced TdP, and based on this and
previous findings the benefit2risk profile of AZD1305 was
considered unfavourable. The AZD1305 development programme
has been discontinued.
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